कृपया अन्य खोज का प्रयास करें
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jesús Prieto | - | - | Member of Scientific Advisory Board |
Robin Ali | - | - | Member of Scientific Advisory Board |
Michael R. Hayden | 72 | - | Member of Scientific Advisory Board |
Katherine A. High | 71 | - | Member of Scientific Advisory Board |
Robert Gut | 58 | 2018 | Non-Executive Director |
David D. Meek | 60 | 2018 | Independent Chairman of the Board |
Paula Soteropoulos | 55 | 2013 | Independent Non-Executive Director |
Madhavan Balachandran | 72 | 2017 | Independent Non-Executive Director |
Matthew Craig Kapusta | 51 | 2015 | CEO & Executive Director |
Leonard E. Post | 70 | 2020 | Independent Non-Executive Director |
Jeremy P. Springhorn | 61 | 2017 | Independent Non-Executive Director |
Jack L. Kaye | 79 | 2016 | Independent Non-Executive Director |
Rachelle Suzanne Jacques | 52 | 2021 | Non-Executive Director |
Hugo Katus | - | 2014 | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है